Company: SXTPW
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-014334
Chunk: 29

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-14
Form: S-1
Chunk 29
---
 our products to Russia nor do we anticipate supplying any of our products to Russia in the near future. Recent Developments Registered Direct Offerings February 2025 On February 5, 2025, we entered into a securities purchase agreement (the “February 2025 Securities Purchase Agreement”) with certain institutional investors (the “February 2025 Purchasers”) pursuant to which the Company sold, in a registered direct offering an aggregate of 1,503,500 shares (the “February 2025 Shares”) of common stock at a purchase price of $0.715 per share in a registered direct offering priced at-the-market under the rules of Nasdaq. The February 2025 Shares were offered pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-280796), which was declared effective by the Securities and Exchange Commission (the “SEC”) on July 18, 2024 as supplemented by a prospectus supplement dated February 5, 2025, filed with the SEC on February 6, 2025 and accompanying base prospectus, pursuant to Rule 424(b)(5) promulgated under the Securities Act. In a concurrent private placement, the Company also issued to the February 2025 Purchasers unregistered warrants to purchase up to an aggregate of 1,503,500 shares of common stock at an exercise price of $0.59 per share. The February 2025 Common Warrants are exercisable upon issuance and expire twenty-four months from the date of issuance. Pursuant to the February 2025 Securities Purchase Agreement, the Company is required to file a registration statement with the SEC within 45 days after the date of the February 2025 Securities Purchase Agreement to register the shares underlying the February 2025 Common Warrants under the Securities Act. The Company shall use commercially reasonable efforts to cause such registration statement to become effective within 75 days following the closing date of the February 2025 Offering and to keep such registration statement effective at all times until no February 2025 Purchaser owns any February 2025 Common Warrants or shares underlying the February 2025 Common Warrants issuable upon exercise thereof. Any holder will not have the right to exercise any portion of the February 2025 Common Warrants if the holder (together with its affiliates) would beneficially own more than 4.99% (or, upon the election of the holder, 9.99%) of the number of shares of the common stock outstanding immediately after